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PLong-Term Outcome of a Routine Versus
Selective Invasive Strategy in Patients With
Non–ST-Segment Elevation Acute Coronary Syndrome
A Meta-Analysis of Individual Patient Data
Keith A. A. Fox, BSC, MB, CHB,* Tim C. Clayton, BSC, MSC,† Peter Damman, MD,‡
Stuart J. Pocock, BSC, MSC, PHD,† Robbert J. de Winter, MD, PHD,‡ Jan G. P. Tijssen, PHD,‡
Bo Lagerqvist, MD, PHD,§ Lars Wallentin, MD, PHD,§ for the FIR Collaboration
Edinburgh and London, United Kingdom; Amsterdam, the Netherlands; and Uppsala, Sweden
Objectives This study was designed to determine: 1) whether a routine invasive (RI) strategy reduces the long-term frequency of
cardiovascular death or nonfatal myocardial infarction (MI) using a meta-analysis of individual patient data from all
randomized studies with 5-year outcomes; and 2) whether the results are influenced by baseline risk.
Background Pooled analyses of randomized trials show early benefit of routine intervention, but long-term results are incon-
sistent. The differences may reflect differing trial design, adjunctive therapies, and/or limited power. This meta-
analysis (n  5,467 patients) is designed to determine whether outcomes are improved despite trial differences.
Methods Individual patient data, with 5-year outcomes, were obtained from FRISC-II (Fragmin and Fast Revascularization
during Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coro-
nary Syndromes), and RITA-3 (Randomized Trial of a Conservative Treatment Strategy Versus an Interventional
Treatment Strategy in Patients with Unstable Angina) trials for a collaborative meta-analysis. A Cox regression
analysis was used for a multivariable risk model, and a simplified integer model was derived.
Results Over 5 years, 14.7% (389 of 2,721) of patients randomized to an RI strategy experienced cardiovascular death or
nonfatal MI versus 17.9% (475 of 2,746) in the selective invasive (SI) strategy (hazard ratio [HR]: 0.81, 95% confidence
interval [CI]: 0.71 to 0.93; p  0.002). The most marked treatment effect was on MI (10.0% RI strategy vs. 12.9% SI
strategy), and there were consistent trends for cardiovascular deaths (HR: 0.83, 95% CI: 0.68 to 1.01; p  0.068) and
all deaths (HR: 0.90, 95% CI: 0.77 to 1.05). There were 2.0% to 3.8% absolute reductions in cardiovascular death or
MI in the low- and intermediate-risk groups and an 11.1% absolute risk reduction in highest-risk patients.
Conclusions An RI strategy reduces long-term rates of cardiovascular death or MI and the largest absolute effect in seen in higher-
risk patients. (J Am Coll Cardiol 2010;55:2435–45) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.007b
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tndividual randomized trials of interventional strategies in
on–ST-segment elevation acute coronary syndrome (ACS)
ave reported short- (1–7) or longer-term outcomes (8–10),
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Manuscript received February 10, 2010; revised manuscript received March 4,
010, accepted March 11, 2010.ut with differing conclusions. Uncertainty remains regard-
ng the long-term benefits versus hazards of a routine early
nvasive strategy (angiography followed by revascularization
here clinically indicated), and whether the outcomes are
ependent on the baseline risk of patients (11–15). Whereas
arly results of some trials (FRISC-II [Fragmin and Fast
evascularization during Instability in Coronary Artery
isease], RITA-3 [Randomized Trial of a Conservative
reatment Strategy Versus an Interventional Treatment
trategy in Patients with Unstable Angina], TACTICS–
IMI 18 [Treat Angina with Aggrastat and Determine
ost of Therapy with an Invasive or Conservative Strategy–
hrombolysis In Myocardial Infarction 18]) showed bene-
ts (4–6), especially in reduced rates of myocardial infarc-
ion (MI) and refractory angina, there was no evidence of
enefit in the ICTUS [Invasive Versus Conservative Treat-
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dromes] trial (7). Moreover,
longer-term mortality and car-
diovascular (CV) mortality re-
sults of the individual trials ap-
pear inconsistent and showed
either no benefit or trends at the
margins of statistical significance
(8–10), illustrating a lack of sta-
tistical power for any 1 trial to
each definitive conclusions. Previous pooled analyses have
ot been conducted using individual patient data, and
utcome data beyond 1 year were not included (14–16).
Differences in outcomes in the respective trials may be the
esult of differences in inclusion criteria, differences in
aseline characteristics of the patients, differences in the
iming and threshold for revascularization, differences in
djunctive therapies, and other factors including the play of
hance. An overall long-term meta-analysis is therefore
equired to define more reliably the relative risks and
enefits of routine invasive (RI) and conservative strategies,
articularly for CV mortality and nonfatal MI. Such an
nalysis would have substantially greater power to determine
he impact on mortality and to explore how the effects
epend on patients’ baseline risk.
The FIR (FRISC-II, ICTUS, RITA-3) collaboration in-
olves the 3 randomized trials with long-term outcome data
5-year outcome) with the hypothesis is that the meta-analysis
ill provide evidence of a reduced rate of CV death or MI
ssociated with an RI strategy compared with a selective
nvasive (SI) strategy. The secondary hypothesis was that
elative and absolute differences between the treatment strate-
ies were influenced by the baseline risk of the patients.
esolving these issues has the potential to influence triage
ecisions for the spectrum of patients presenting with non–
T-segment elevation ACS and guidelines suggest the impor-
ance of risk stratification (11–13).
ethods
tudy population and procedures. A computerized liter-
ture search was conducted from 1970 to 2009 of the
EDLINE and Cochrane databases by using terms that
ncluded: “invasive strategy,” “conservative strategy,” “selec-
ive invasive strategy,” “intervention,” “acute coronary syn-
romes,” “non–ST-segment elevation myocardial infarc-
ion,” and “unstable angina.” Three randomized trials with
ong-term outcomes were identified that met these criteria
FRISC-II, RITA-3, and ICTUS) (8–10). The TACTICS–
IMI 18 trial has only 6-month outcome data (5), and none
f the smaller trials has 5-year outcomes published or
resented (1–3,14–16).
Individual outcomes and the design of the FRISC-II,
ITA-3, and ICTUS trials have been reported previously
8–10). The previous publication of RITA-3 reported
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CV  cardiovascular
MI  myocardial infarction
RI  routine invasive
SI  selective invasiveutcomes at a median of 5 years, and for consistency across che trials, the results are now extended with complete 5-year
ollow-up for all patients.
These trials compared an RI strategy with an SI strategy
n patients with non–ST-segment elevation ACS but with
iffering criteria for the eligible population. The RI strategy
onsisted of “early” coronary angiography and the timing of
his reflected contemporary clinical practice (within 24 to
8 h of randomization in ICTUS, within 72 h in RITA-3,
nd within 7 days in FRISC-II). The decision to proceed to
ercutaneous or surgical revascularization was based on the
ngiographic findings, but the threshold for proceeding to
ntervention differed in the 3 trials. In each trial, the SI
conservative” strategy consisted of initial medical treatment
ith coronary angiography and revascularization only for
efractory or an accelerating pattern of angina despite
ptimal medical treatment (or in the case of hemodynamic
r rhythmic instability in ICTUS). In the FRISC-II and
CTUS trials, a pre-discharge ischemia detection test was
ystematically performed, with criteria for “crossing over” to
ntervention from the SI strategy (4,7,9,10). By design, in
ITA-3 the indication for coronary arteriography in the SI
trategy was symptom-driven (6,8).
etting and data collection. The principal investigators
f FRISC-II, RITA-3, and ICTUS (L. W., K. A. A. F.,
. J. d.W.) initiated this collaborative analysis, and a
rotocol was written summarizing the main pre-specified
nalyses and a common set of baseline and outcome vari-
bles. Investigators from the 3 trials provided individual
atient data to form a pooled patient database in accordance
ith previously published methodologies (1–3,5,13–16).
he database included core variables on demographics,
linical history, risk factors for coronary artery disease,
aseline electrocardiographic characteristics, biomarkers of
yocardial necrosis, and 5-year clinical outcomes. Data sets
rom each trial were sent for merging to the coordinating
cademic Medical Center in Amsterdam, the Netherlands.
he merged database was checked for completeness and
onsistency by all 3 participating sites.
utcomes. The primary outcome was the composite of
V death or nonfatal MI. Other secondary outcomes
ncluded all-cause death and nonfatal MI alone. Myocardial
nfarction was defined as pre-specified in each trial (4,6,7).
tatistical analysis. The main outcomes were tabulated by
reatment group for each study, and overall, with 5-year
umulative event rates estimated with the Kaplan-Meier
ethod. The impact of the intervention was assessed using
ox regression models, stratified by trial. For the primary
utcome of CV death or nonfatal MI, heterogeneity be-
ween treatment strategy and study was assessed using an
nteraction test in the Cox model. Univariable associations
f the candidate baseline variables with the primary out-
ome were determined from the combined data. A forward
tepwise Cox regression model was used to develop a
ultivariable model of key predictors of CV death or
onfatal MI with p  0.01 by the Wald test used as the
riterion for inclusion in the model. No adjustment for trial
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isk score based only on patient baseline factors. However, a
odel with trial entered as dummy variables was performed
o assess whether this materially altered the hazard ratios for
ach predictor included.
The coefficients in the final Cox model were rounded to
roduce an integer risk score to predict a patient’s 5-year
robability of CV death or MI. For each risk factor a score
f 0 is assigned to the lowest risk category and an individ-
al’s score increases by an integer amount for each level
bove the lowest category (with 1 unit increase in the integer
core equating to approximately each 0.2 increase in the
oefficient). In order to assess the effect of intervention
ccording to risk, the integer score was calculated assuming
he patient received the SI strategy. Patients were then
ategorized into 3 risk groups (each of the 3 groups
ontained approximately one-third of the primary outcome
vents). The percentage of patients with the primary out-
ome was tabulated by treatment group and risk category,
long with hazard ratios and absolute risk differences, to
onsider whether the impact of intervention depended on
nderlying risk.
Risk categories were also defined based on the exact coeffi-
ients from the model to compare the results with those using
he simple integer score. Finally, risk categorizations were used
o assess the impact of intervention on CV mortality and for
ll-cause mortality. All analyses were carried out using Stata
ersion 10.1 (StataCorp, College Station, Texas).
esults
haracteristics of the patients. Three randomized trials
ad outcome information with a minimum of 5 years of
ollow-up and the data were censored at 5 years. Overall,
,746 patients were assigned an SI (“conservative”) strategy
nd 2,721 patients an RI strategy.
The mean age was 63.3 years, body mass index was 27.2
g/m2 and 68.0% of the population were men (baseline
ariables in the respective studies: Table 1).
Comparing the baseline characteristics across the 3 trials,
he majority of the patient demographics, the key risk
actors, and the extent of prior coronary artery disease were
imilar (Table 1). Almost one-half of the patients (47.3%)
ad ST-segment deviation at presentation. There were
ifferences in baseline characteristics in respective trials
ncluding a higher proportion of patients presented with
T-segment depression on the admission electrocardiogram
n FRISC-II (47.1%) and ICTUS (44.6%) than in RITA-3
36.5%) (Table 1). Troponin values were not available at
aseline in all patients in RITA-3.
evascularization rates over time. Among those ran-
omized to an RI strategy, approximately two-thirds
64.1%) underwent revascularization during the index
ospitalization; this figure rising to 71.8% at the end of 1
ear and 73.3% at the end of 3 years. In comparison, the 9ate of revascularization in hospital in those randomized
o an SI strategy was 17.6% but this rose to 41.6% at the
nd of 1 year and 47.8% at the end of 3 years (Kaplan-
eier plot) (Fig. 1). By design, the individual trials
llowed for angiography and revascularization on the
asis of symptoms and objective signs of ischemia (4,6,7)
nd routine pre-discharge stress testing led to higher
rossover rates to intervention in the SI strategy patients,
articularly in ICTUS (7,10). The Kaplan-Meier plot of
evascularization over time shows that most of those
rossing to intervention from the SI strategy had revas-
ularization performed within 3 months of presentation
Fig. 1). Considering all revascularizations, there were
.71 per patient in the RI group compared with 0.44 per
atient in the SI group (RITA-3) (Fig. 1).
mpact of the randomized treatment: overall clinical
utcomes. Over the course of 5 years, 14.7% (389 of 2,721)
f patients randomized to an RI strategy experienced CV
eath or nonfatal MI compared with 17.9% (475 of 2,746)
andomized to the SI strategy (hazard ratio [HR]: 0.81,
aseline Characteristics by Study*Table 1 Baseline Characteristics by Study*
FRISC-II
(n  2,457)
RITA-3
(n  1,810)
ICTUS
(n  1,200)
Age, yrs 64.6 (9.1) 62.4 (10.3) 61.9 (10.6)
55 470 (19.1%) 433 (23.9%) 298 (24.8%)
55–60 179 (7.3%) 263 (14.5%) 210 (17.5%)
60–65 475 (19.3%) 316 (17.5%) 163 (13.6%)
65–70 567 (23.1%) 295 (16.3%) 176 (14.7%)
70–75 305 (12.4%) 277 (15.3%) 201 (16.8%)
75 461 (18.8%) 226 (12.5%) 152 (12.7%)
Weight, kg 79.6 (13.5) 78.6 (14.6) 81.5 (12.9)
BMI, kg/m2 26.8 (3.8) 27.7 (4.7) 27.1 (3.7)
Sex
Women 749 (30.5%) 682 (37.7%) 320 (26.7%)
Men 1,708 (69.5%) 1,128 (62.3%) 880 (73.3%)
Smoking
Current 745 (30.3%) 586 (32.4%) 492 (41.0%)
Hypertension 743 (30.2%) 632 (34.9%) 466 (38.8%)
Hyperlipidemia 262 (10.7%) 579 (32.0%) 417 (34.8%)
Diabetes 299 (12.2%) 244 (13.5%) 166 (13.8%)
Previous MI 546 (22.2%) 501 (27.7%) 278 (23.2%)
Previous PCI 80 (3.3%) 93 (5.1%) 140 (11.7%)
Previous CABG 9 (0.4%) 0 (0.0%) 105 (8.8%)
ST-segment depression 1,152 (47.1%) 660 (36.5%) 513 (44.6%)
ST-segment elevation 202 (8.3%) 139 (7.7%) 137 (11.9%)
ST-segment deviation 1,240 (50.7%) 742 (41.0%) 574 (50.0%)
alues are mean (SD) or n (%). In total, of those discharged alive, 62.0% were discharged on a
tatin (RI: 61.9%, SI: 62.1%), 93.2% on aspirin (RI: 92.4%, SI: 94.0%), 80.6% on a beta-blocker (RI:
8.6%, SI: 82.6%), and 22.7% on an angiotensin-converting enzyme inhibitor (RI: 22.4%, SI:
2.9%). *For assessing differences in baseline characteristics across the 3 studies, p  0.001 for
ach variable except diabetic status (p  0.27).
BMI  body mass index; CABG  coronary artery bypass graft; FRISC-II  Fragmin and Fast
evascularization during Instability in Coronary Artery Disease; ICTUS  Invasive Versus Conser-
ative Treatment in Unstable Coronary Syndromes; MI  myocardial infarction; PCI  percutane-
us coronary intervention; RI  routine invasive; RITA-3  Randomized Trial of a Conservative
reatment Strategy Versus an Interventional Treatment Strategy in Patients with Unstable Angina;
I  selective invasive.5% confidence interval [CI]: 0.71 to 0.93; p  0.002)
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djustment for study (Fig. 2). Including all periprocedure
nfarctions (Table 2), the data for FRISC-II and RITA-3
re unchanged and for ICTUS there were 14 additional
atients with MIs with SI but 32 additional patients with
Is for the RI strategy. In consequence, combined, there
ere 487 (18.3%) CV deaths or MIs with SI and 420
15.9%) with an RI strategy: HR: 0.86, 95% CI: 0.76 to
.98; p  0.028. Considering deaths from any cause or
onfatal MIs, the findings were similar with a 15% hazard
eduction for the RI strategy (HR: 0.85, 95% CI: 0.75 to
.96; p  0.008) (Table 2). The most marked treatment
ffect was seen for nonfatal MIs that occurred in 10.0% of
he population randomized to a RI strategy versus 12.9% to
n SI strategy (HR: 0.77, 95% CI: 0.65 to 0.90; p  0.001).
There were numerically fewer CV deaths among those
andomized to a RI strategy (6.8%) versus those random-
zed to a SI strategy (8.1%) (HR: 0.83, 95% CI: 0.68 to
.01; p  0.068) (Table 2). Deaths from any cause were
lso numerically fewer among those randomized to a RI
trategy (10.6% vs. 11.7% in the SI strategy, p  0.19)
lthough this difference is not statistically significant
Table 2).
Comparing the outcomes across the trials, the hazard
atios for the composite of CV death or nonfatal MI
emonstrated similar findings in FRISC-II (HR: 0.79, 95%
I: 0.66 to 0.95) and RITA-3 (HR: 0.75, 95% CI: 0.58 to
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Figure 1 Timing of First Coronary Revascularization
All revascularizations: For routine invasive (RI) strategy, the total number of revasc
Versus an Interventional Treatment Strategy in Patients with Unstable Angina) trial
(in 347 patients) for RITA-3. The data on total revascularizations are not available
Disease) or ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary S
and 750 had coronary artery bypass graft (CABG) as their first procedure (1,998 p
(1,317 patients total)..96), and in both studies the confidence bounds did not vverlap unity (Fig. 2). In ICTUS, the confidence bounds
verlapped with those of the other 2 studies and with unity
HR: 0.99, 95% CI: 0.72 to 1.35) (Fig. 2). There is no evidence
f heterogeneity between trials (interaction p  0.37).
The Kaplan-Meier plots for CV death or nonfatal MI
emonstrate early separation of the curves in favor of the RI
trategy with sustained separation and slight divergence over
he course of the 5 years of follow-up (Fig. 3).
ultivariable predictors for CV death or MI at 5 years of
ollow-up. The univariable and multivariable predictors of
V death or nonfatal MI were derived (Tables 3 and 4).
he independent multivariable predictors for CV death or
I in the entire dataset were randomized treatment (HR:
.76, 95% CI: 0.67 to 0.87; p  0.0001), age per 5-year
nterval, diabetes, prior MI, presentation with ST-segment
epression, hypertension, and low (25 kg/m2) or elevated
ody mass index (35 kg/m2) (Table 4).
he relation between baseline risk and outcome at 5 years
f follow-up. In the high-risk RI group there were 130 of
23 CV deaths or nonfatal MIs (32.1%) versus 159 of 379
43.8%) in the SI group (HR: 0.66, 95% CI: 0.52 to 0.83,
isk difference: –11.7%). In the moderate-risk patients (29%
f the cohort), the respective figures for the RI group were
34 of 791 (17.4%) versus 152 of 774 for the SI group
20.3%) (HR: 0.86, 95% CI: 0.68 to 1.08, risk difference:
2.9%). In the low-risk patients (56% of the cohort), the
espective figures for the RI group were 125 of 1,507 (8.5%)
3 4 5
1147 1004 871
-up time (years)
591 537 459
tions was 633 in RITA-3 (Randomized Trial of a Conservative Treatment Strategy
6 patients). In the selective invasive (SI) strategy, the respective figures are 406
RISC-II (Fragmin and Fast Revascularization during Instability in Coronary Artery
mes) trials. In the RI group, 1,248 had percutaneous coronary intervention (PCI)
total). In the SI group, 748 had PCI and 569 had CABG as their first procedureasive
sive
2
1384
ollow
699
ulariza
(in 54
from F
yndro
atientsersus 164 of 1,593 for the SI group (10.6%) (HR: 0.80,
9
d
c
a
(
o
t

n

0
m
a
n
c
l
w
c
c
C
(
1
t
o
t
5
w
0
–
m
m
–
C
C
w
o
0
T
m
0
–
r
(
(
M
h
t
n
w
s
mtc
om
es
by
S
tu
dy
an
d
Tr
ea
tm
en
t
ab
le
2
O
ut
co
m
es
by
S
tu
dy
an
d
Tr
ea
tm
en
t
O
ut
co
m
es
*
FR
IS
C
-II
R
IT
A
-3
IC
TU
S
C
om
bi
ne
d
H
R
(9
5
%
C
I)
p
V
al
ue
S
I
(n

1
,2
3
5
)
R
I
(n

1
,2
2
2
)
S
I
(n

9
1
5
)
R
I
(n

8
9
5
)
S
I
(n

5
9
6
)
R
I
(n

6
0
4
)
S
I
(n

2
,7
4
6
)
R
I
(n

2
,7
2
1
)
ll-
ca
us
e
de
at
h
1
2
4
(1
0
.1
%
)
1
1
7
(9
.6
%
)
1
3
8
(1
5
.1
%
)
1
0
4
(1
1
.6
%
)
5
9
(9
.9
%
)
6
7
(1
1
.1
%
)
3
2
1
(1
1
.7
%
)
2
8
8
(1
0
.6
%
)
0
.9
0
(0
.7
7

1
.0
5
)
0
.1
9
V
de
at
h
8
6
(7
.1
%
)
7
9
(6
.6
%
)
9
2
(1
0
.3
%
)
6
4
(7
.3
%
)
4
0
(6
.8
%
)
3
8
(6
.5
%
)
2
1
8
(8
.1
%
)
1
8
1
(6
.8
%
)
0
.8
3
(0
.6
8

1
.0
1
)
0
.0
6
8
I
2
0
6
(1
7
.6
%
)
1
5
0
(1
2
.9
%
)
7
8
(8
.9
%
)
6
0
(6
.9
%
)
5
4
(9
.4
%
)
5
0
(8
.6
%
)
3
3
8
(1
2
.9
%
)
2
6
0
(1
0
.0
%
)
0
.7
7
(0
.6
5

0
.9
0
)
0
.0
0
1
ll-
ca
us
e
de
at
h/
M
I
2
8
3
(2
3
.8
%
)
2
3
1
(1
9
.7
%
)
1
8
2
(2
0
.2
%
)
1
4
4
(1
6
.3
%
)
9
5
(1
6
.1
%
)
1
0
5
(1
7
.5
%
)
5
6
0
(2
0
.9
%
)
4
8
0
(1
8
.1
%
)
0
.8
5
(0
.7
5

0
.9
6
)
0
.0
0
8
V
de
at
h/
M
I
2
5
4
(2
1
.4
%
)
2
0
4
(1
7
.4
%
)
1
4
3
(1
6
.1
%
)
1
0
7
(1
2
.2
%
)
7
8
(1
3
.4
%
)
7
8
(1
3
.2
%
)
4
7
5
(1
7
.9
%
)
3
8
9
(1
4
.7
%
)
0
.8
1
(0
.7
1

0
.9
3
)
0
.0
0
2
rc
en
ta
ge
s
ar
e
K
ap
la
n-
M
ei
er
pe
rc
en
ta
ge
s
at
5
ye
ar
s.
In
cl
ud
in
g
al
lp
er
ip
ro
ce
du
re
in
fa
rc
tio
ns
,t
he
da
ta
fo
rF
R
IS
C
-II
an
d
R
IT
A
-3
ar
e
un
ch
an
ge
d,
an
d
fo
rI
C
TU
S
,t
he
re
w
er
e
1
4
ad
di
tio
na
lM
Is
in
th
e
S
Is
tr
at
eg
y
an
d
3
2
ad
di
tio
na
lM
Is
in
th
e
R
Is
tr
at
eg
y.
In
co
ns
eq
ue
nc
e,
co
m
bi
ne
d,
e
w
er
e
4
8
7
(1
8
.3
%
)
C
V
de
at
h/
M
Is
in
th
e
S
Ia
nd
4
2
0
(1
5
.9
%
)
in
th
e
R
Ig
ro
up
s:
ha
za
rd
ra
tio
(H
R
):
0
.8
6
,9
5
%
co
nfi
de
nc
e
in
te
rv
al
(C
I)
:0
.7
6
to
0
.9
8
,p

0
.0
2
8
.

ca
rd
io
va
sc
ul
ar
;o
th
er
ab
br
ev
ia
tio
ns
as
in
Ta
bl
e
1
.
2439JACC Vol. 55, No. 22, 2010 Fox et al.
June 1, 2010:2435–45 Long-Term Impact of Interventional Strategy in ACS5% CI: 0.63 to 1.01, risk difference: –2.1%). These risk
ifferences are based on the exact coefficients. These agree
losely with the simplified integer score.
In order to make the multivariable risk prediction more
ccessible to clinicians, it was converted into an integer score
Table 5, Fig. 4). The simple integer scoring system is based
n the multivariable predictors: age:60 years 0 score, 60
o 64 years1, 65 to 69 years2, 70 to 74 years3,
75 years 5; diabetes: no  0, yes  4; hypertension:
o  0, yes  1; ST-segment depression: no  0, yes 
2; body mass index:25 kg/m21, 25 to35 kg/m2
,35 kg/m22 (Fig. 6). We formed 3 risk groups: low,
oderate, and high risk for integer scores of 0 to 4, 5 to 8,
nd 9, respectively. The aim was to have roughly equal
umbers of primary outcomes in each risk group. As a
onsequence there are substantially more patients in the
ow-risk group and fewer in the high-risk group, compared
ith the moderate-risk group (Table 5). The risk stratifi-
ation demonstrated separation of outcome according to the
ategories of risk. For both strategies, the combined rate of
V death or nonfatal MI was 9.3% in the low-risk group
263 of 2,926), 19.2% in the moderate-risk group (341 of
,832), and 38.2% in the high-risk group (260 of 709). As
here was no significant heterogeneity in the relative effect on
utcome over the risk groups, the absolute impact of interven-
ion differed in relation to the category of baseline risk (Table
, Fig. 5). The largest absolute reduction in CV death or MI
as seen in the 13% of patients in the highest risk group (HR:
.68, 95% CI: 0.53 to 0.86; risk difference –11.1%, 95% CI:
18.4% to –3.8%). The lower rates of outcome events in the
oderate- and lower-risk groups were associated with more
odest reductions in absolute event rates of –3.8% (95% CI:
7.4% to –0.1%) in the moderate-risk group and –2.0% (95%
I: –4.1% to 0.1%) in the low-risk group.
ardiovascular and all-cause mortality and risk group. There
as a lower rate of CV mortality in the high-risk RI group (82
f 378 versus 84 of 331 for the SI group [HR: 0.83, 95% CI:
.61 to 1.12; risk difference: –3.8%, 95% CI: –10.3% to 2.7%]).
he high-risk RI group also showed a lower rate of all-cause
ortality (107 of 378 vs. 107 of 331 for the SI group [HR:
.84, 95% CI: 0.65 to 1.10; risk difference: –4.0%, 95% CI:
10.9% to 2.8%]). There were smaller but consistent absolute
eductions even in the low-risk group for both CV mortality
–1.1%, 95% CI: –2.3% to 0.1%) and all-cause mortality
–0.9%, 95% CI: –2.5% to 0.7%).
Thus the largest absolute difference in CV death or
I, and in all-cause and CV mortality, was seen in the
ighest risk group. The test for interaction between
reatment and risk score for CV death or MI was
onsignificant on the hazard ratio scale (p  0.10),
hereas it was highly significant on the risk difference
cale (p  0.0001); hence, the results are consistent with
ore modest treatment effects (in terms of absolutedifferences) in lower risk groups.Ou T
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Figure 2 Meta-Analyses for CV Death or MI (FRISC-II, RITA-3, ICTUS Studies)
Meta-analyses for (A) cardiovascular (CV) death or myocardial infarction (MI), (B) CV death only, and
(C) MI only combined across FRISC-II, RITA-3, and ICTUS trials. Abbreviations as in Figure 1.
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his meta-analysis of the 3 trials that assessed the long-term
mpact of a RI strategy demonstrated a sustained advantage for
he RI strategy in reducing subsequent CV death or nonfatal
I. The 19% relative risk reduction (HR: 0.81, 95% CI: 0.71
o 0.93) reflected a 3.2% absolute reduction in the combined
nd point. The difference was mainly driven by the 23%
elative 2.9% absolute reduction in MI. However, there was
lso a consistent strong trend to a reduction in cardiovascular
nd total mortality. The randomized treatment was applied on
op of the contemporary standard of secondary prevention
herapy and the treatment effect was seen despite the fact that
djunctive therapy and instrumentation evolved over the course
f the successive trials (e.g., use of thienopyridines, glyco-
rotein IIb/IIIa antagonists, stent and catheter technology).
urthermore, the benefit was seen despite a substantial cross-
ver to invasive treatment event in the noninvasive treatment
rm in several of the trials.
The hypothesis has been proposed that the timing of
evascularization influences outcome but the most recent and
argest of the studies (17) of timing did not demonstrate overall
enefit of an early routine intervention compared with a
elayed routine intervention (17–20).
esolving the differences in outcome compared with
ndividual studies. Previous combined analyses have not
een conducted using individual patient data, and they lacked
utcomes beyond a year (14–16). Why are the findings more
lear-cut in this meta-analysis compared with individual trials?
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Figure 3 Cumulative Risk of CV Death or MI
Patients (n  5,467) and follow-up: There were 4,084 patients without a primary e
points and 194 other deaths. A further 38 patients were lost to follow-up and 287irst, the substantially greater sample size, and second, the rreater number of outcome events over 5 years. Individual trials
ad limited statistical power for cardiovascular death or MI.
hey either had composite end points (RITA-3, ICTUS), or
hey were powered for a large anticipated (33%) reduction in
eath or MI (FRISC-II) (14–16).
What accounts for the trial-to-trial differences in outcomes?
irst, there were different inclusion criteria in the trials with
ore unselected populations included in the first performed
rials—FRISC-II and RITA-3. In the ICTUS study, patients
ncluded were all troponin-positive and had either ischemic chest
ain or documented coronary artery disease. This may in part
xplain the high revascularization rate in the SI arm of ICTUS.
In FRISC-II and RITA-3, there was a wide separation in
he frequency of early and late revascularization rates between
he 2 arms of the respective trials. In FRISC-II, the revascu-
arization rates were 71% within 10 days and 78% within 12
onths in the RI group. This compares with 9% and 43%,
espectively, in the SI group. In RITA-3, for the RI group, the
evascularization rates were 44% within index hospitalization
nd 57% within 12 months compared with 10% and 28%,
espectively, in the SI group. In ICTUS, for the RI group, 76%
ithin index hospitalization and 79% within 12 months
ompared with 40% and 54%, respectively, in the SI group.
hus, especially the early rate of revascularization in the SI
trategy was substantially higher in ICTUS than in FRISC-II
r RITA-3, and the rate remained higher thereafter. In
ITA-3, the rates of both early and late intervention, in the SI
nd RI strategies were lower than in FRISC-II and ICTUS. In
act, the rate of intervention in the SI arm of ICTUS
3 4 5
2178 2077 2005
-up time (years)
2235 2166 2079
CV death or MI) who were followed for 5 years. There were 864 primary end
red because follow-up time differed from 5 years. Abbreviations as in Figure 2.asive
sive
2
2351
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2410
vent (
censoesembled the rate in the RI arm of RITA-3.
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Long-Term Impact of Interventional Strategy in ACS June 1, 2010:2435–45o the outcomes differ according to the extent of baseline
V risk? To resolve this issue, univariable (Table 3) and
ultivariable predictors (Table 4) of CV death or MI were
erived and the entire population was separated into 3
roups based on an integer score so that each risk group
ontained approximately one-third of the outcome
vents. The identified risk characteristics and the results
n the different risk groups correspond well to previous
eports from the FRISC-II trial (9,21). The most pro-
ounced treatment effect was seen in the high-risk group.
owever, although the treatment effect was less pro-
ounced in the majority of patients at lower risk, the
Univariable Associations With CV Death or MITable 3 Univariable Associations With CV D
Risk Factor Categories Outcom
Randomized treatment SI
RI
Study FRISC-II
RITA-3
ICTUS
Age Per 5-yr increase
55
5560
6065
6570
7075
75
Weight Per 10-kg increase
BMI Per kg/m2 increase
25
2530
3035
35
Sex Women
Men
Smoking No
Yes
Hypertension No
Yes
Hyperlipidemia No
Yes
Diabetes No
Yes
Previous MI No
Yes
Previous PCI No
Yes
Previous CABG No
Yes
ST-segment depression No
Yes
ST-segment elevation No
Yes
ST-segment deviation No
Yes
Abbreviations as in Tables 1 and 2.bsolute number of events prevented was greater (20 tvents in the high-risk group, 31 events in the
ntermediate-risk, and 35 events in the low-risk patients
Table 5). Interestingly, the Kaplan-Meier plot suggests
hat the early invasive strategy is associated with a
rogressive benefit over time that may reflect a long-term
educed rate of MI because of avoidance of risk of
pisodes of ischemia and avoidance of the consequences
f earlier myocardial injury on subsequent arrhythmic
vents and heart failure (increasing risk of CV mortality).
The relative and absolute benefits in the moderate and lower
isk groups are of similar magnitude to those aimed for and
een in the overall results of recent trials of pharmaceutical
or MI
enominator HR 95% CI p Value
,746 1.00 —
,721 0.81 0.71–0.93 0.002
,457 1.00 —
,810 0.70 0.60–0.82 0.001
,200 0.65 0.54–0.78 0.001
1.25 1.20–1.29 0.001
,201 1.00 — 0.001
52 0.96 0.70–1.31
54 1.42 1.10–1.83
,038 1.77 1.40–2.25
83 2.20 1.73–2.79
39 3.28 2.63–4.10
0.98 0.93–1.03 0.44
0.96 0.89–1.05 0.39
,633 1.00 — 0.005
,625 0.82 0.70–0.95
70 0.82 0.66–1.01
60 1.24 0.93–1.66
,751 1.00 —
,716 1.10 0.95–1.27 0.20
643 1.00 —
,823 0.75 0.65–0.87 0.001
,626 1.00 —
,841 1.52 1.33–1.74 0.001
,208 1.00 —
,258 1.13 0.97–1.31 0.13
,758 1.00 —
09 2.37 2.03–2.77 0.001
,142 1.00 —
,325 2.07 1.80–2.37 0.001
,154 1.00 —
13 1.25 0.96–1.62 0.097
,353 1.00 —
14 1.60 1.10–2.33 0.014
,080 1.00 —
,325 1.58 1.38–1.81 0.001
,925 1.00 —
78 1.27 1.02–1.58 0.030
,849 1.00 —
,556 1.55 1.36–1.78 0.001eath
es/D
475/2
389/2
458/2
250/1
156/1
—
115/1
60/6
127/9
169/1
156/7
237/8
—
—
283/1
383/2
126/8
55/2
261/1
603/3
626/3
238/1
494/3
370/1
646/4
218/1
653/4
211/7
533/4
331/1
803/5
61/3
836/5
28/1
400/3
451/2
758/4
92/4
367/2
484/2reatments for non–ST-segment elevation ACS: TRITON–
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omes by Optimizing Platelet Inhibition with Prasugrel–
hrombolysis In Myocardial Infarction 38) (22) and PLATO
Platelet Inhibition and Patient Outcomes) (23). How-
ver, the health economic considerations of the smaller
umber needed to treat per patient saved in the higher
isk subgroup but greater number of patients saved by
reating also lower risk populations need greater attention
hen interpreting how trial findings are best applied to
uture patients (24). In contrast to these findings from
andomized trials, studies of clinical practice in multiple
ountries demonstrate a “treatment-risk paradox,”
hereby most interventions are performed in lower risk
atients (25,26).
an this risk model be converted into a readily usable
nteger risk predictor? The simplified integer score demon-
trates very similar separation of the risk groups and similar risk
ifferences compared with the exact coefficients from the
odel used to determine risk. This integer score has the
otential to be applied at the bedside, and without the need for
nomogram or calculator. The receiver operator characteristic
or the integer score was 0.69, which is almost identical to the
core for the full multivariable model. The FRISC-II, RITA 3,
nd ICTUS studies lacked the variables necessary to apply
ther well-validated risk scores (e.g. TIMI, GRACE) (11–13).
ultivariable Predictors ofV De th or MI (Cox Regression)Table 4 ultivariable Predictors ofCV Death or MI (Cox Regression)
Risk Factor HR 95% CI Coefficient z-Score*
Age, per 5 yrs above 60 yrs 1.29 1.23–1.36 0.256 9.89
Diabetes 2.06 1.75–2.41 0.72 8.83
Previous MI 1.83 1.59–2.10 0.60 8.50
ST-segment depression 1.42 1.24–1.63 0.35 5.03
Hypertension 1.26 1.10–1.45 0.23 3.33
BMI, kg/m2†
25 1.25 1.08–1.45 0.22 2.98
2535 1.00 — — —
35 1.52 1.15–2.01 0.42 2.91
Randomized treatment
SI 1.00 — — —
RI 0.76 0.67–0.87 –0.27 –3.91
Absolute value of z 1.96, 2.58, 3.29, 3.89, 4.42 corresponds to p value 0.05, 0.01, 0.001,
.0001, 0.00001, respectively. †p  0.0008 for inclusion of BMI group.
Abbreviations as in Tables 1 and 2.
reatment Effect by Integer Risk Category of CV Death or MITable 5 Treatment Effect by Integer Risk Category of CV Death
Risk Group* Risk Score
Treatment Grou
SI
1st (low) 0–4 149/1,503 (10.2%) 1
2nd (moderate) 5–8 186/912 (21.1%)
3rd (high) 9 140/331 (44.1%)
Total 475/2,746 (17.9%) 3
Risk group determined assuming patient in the SI group and calculated according to approximate
rom 5-year Kaplan-Meier estimates. †Interaction of treatment by integer risk score on the HR scale, p 
Abbreviations as in Tables 1 and 2.trengths and limitations. This is the first meta-analysis of
he long-term impact of a RI strategy, on top of the current
tandard of adjunctive therapy. It is based on individual patient
ata.
Rates of adjunctive therapy increased in each successive
tudy and rates were highest in ICTUS. Rates of intervention
ere also highest in ICTUS. There were differences in the
efinition of MI by study and differences in the sensitivity for
etection of MI. Detection of the early occurrence of re-MI
resents diagnostic challenges in all studies of non–ST-
egment elevation ACS. However, such differences in defini-
ion and diagnostic threshold of biomarkers would tend to add
noise” to the meta-analysis and diminish the probability of
howing any real impact on CV death or MI. The sensitivity
or detection of infarction, including periprocedure infarction
ncreased with successive studies and ICTUS routinely mea-
ured serial blood samples in patients for post-PCI elevations
f creatine kinase-myocardial band (CK-MB) mass. However,
n ICTUS, there was acknowledgment that periprocedure
nfarctions were more readily detected during the initial in-
ospital phase in the RI group than in the SI group (under-
aken later) (10). Specifically, of the 82 patients with MI in the
I group, 35 (42.7%) had procedure-related MIs alone com-
ared with 14 of 68 (20.5%) in the SI group. Nevertheless,
ven including all of these procedure-related MIs in the
eta-analysis, the RI strategy has a reduced rate of CV death
r nonfatal MI (HR: 0.86, 95% CI: 0.76 to 0.98; p  0.028).
The use and sensitivity of biomarkers of necrosis evolved
ver the successive studies. As differing troponin assays were
sed and not all patients had troponin values, this variable was
ot included in the multivariable risk calculation. Nevertheless,
ased on the other independent predictors, patients could be
eparated clearly into the 3 categories of risk (Fig. 5).
Finally, the differences may be influenced by sample size and
he play of chance (ICTUS was the smallest study and had
imited power to resolve differences in death or MI). Never-
heless, as illustrated in Figure 2, the confidence intervals for
utcomes overlap and despite the differences in design, the
eta-analysis strongly suggests a benefit for the RI strategy,
ven 5 years after randomization. This is despite subsequent
ate revascularizations in the selective strategy in each study, on
ccount of symptoms and signs of ischemia.
mplications. Despite differences in trial design and in the
volution of adjunctive therapies and technologies, and indi-
I
HR† (95% CI) Risk Difference‡ (95% CI)RI
423 (8.2%) 0.80 (0.63 to 1.02) –2.0% (–4.1% to 0.1%)
920 (17.3%) 0.81 (0.66 to 1.01) –3.8% (–7.4% to –0.1%)
378 (33.0%) 0.68 (0.53 to 0.86) –11.1% (–18.4% to –3.8%)
721 (14.7%)
of risk among those experiencing CV death or MI. Percentages and risk differences are calculatedor M
p
14/1,
155/
120/
89/2,
thirds
0.10. ‡Interaction of treatment by integer risk score on the risk difference scale, p  0.0001.
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Long-Term Impact of Interventional Strategy in ACS June 1, 2010:2435–45idual differences from trial to trial in outcomes, the overall
eta-analysis at 5 years shows a sustained reduction in the rate
f CV death or MI by using a RI strategy in patients with
on–ST-segment elevation ACS. The largest absolute benefit
s observed in patients with higher baseline risk and such
atients can be identified using simple clinical risk character-
stics. However, even in intermediate- and lower risk popula-
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Integer score components and values: age: 60 years  0, 60 to 64 years  1
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Figure 5 Cumulative Risk of CV Death or MI by Risk Group
The low-, intermediate-, and high-risk groups were divided according to the distribuions, the benefits of an early invasive strategy are of similar
agnitude as those aimed for and seen with current pharma-
ological interventions. It is remarkable that despite the sys-
emic and diffuse nature of atheromatous disease, and disease
rogression elsewhere in the vascular system, an early routine
evascularization strategy has a treatment benefit that is clearly
vident after 5 years.
n selective invasive
n routine invasive
6 7 8 9 10 11 12 13 14 15+ Total
6 7 8 9 10 11 12 13 14 15
Integer score
490 415 331 245 174 139 82 31 15 23 5467
Death or MI at 5 Years
o 69 years  2, 70 to 74 years  3, and 75 years  5; diabetes: no 
2; body mass index (BMI): 25 kg/m2  1, 25 to 35 kg/m2  0, 35
which is almost identical to the score for the full multivariable model.
High
Intermediate
Low
3 4 5
2178 2077 2005
e (years)
2235 2166 2079
outcome events. Abbreviations as in Figure 2. risk o
 risk o
5
5
4 596
of CV
, 65 t
yes 
0.69,-up tim
tion of
R
C
C
E
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2445JACC Vol. 55, No. 22, 2010 Fox et al.
June 1, 2010:2435–45 Long-Term Impact of Interventional Strategy in ACSeprint requests and correspondence: Prof. Keith A. A. Fox,
entre for Cardiovascular Science, The University of Edinburgh,
hancellor’s Building, 49 Little France Crescent, Edinburgh
H16 4SB, United Kingdom. E-mail: k.a.a.fox@ed.ac.uk.
EFERENCES
1. The TIMI IIIB Investigators. Effects of tissue plasminogen activator
and a comparison of early invasive and conservative strategies in
unstable angina and non–Q-wave myocardial infarction: results of the
TIMI IIIB trial. Thrombolysis In Myocardial Ischemia. Circulation
1994;89:1545–56.
2. McCullough PA, O’Neill WW, Graham M, et al. A prospective
randomized trial of triage angiography in acute coronary syndromes
ineligible for thrombolytic therapy: results of the Medicine versus
Angiography in Thrombolytic Exclusion (MATE) trial. J Am Coll
Cardiol 1998;32:596–605.
3. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients
with acute non–Q-wave myocardial infarction randomly assigned to an
invasive as compared with a conservative management strategy (erratum in
N Engl J Med 1998;339:1091). N Engl J Med 1998;338:1785–92.
4. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E.
Outcome at 1 year after an invasive compared with a non-invasive
strategy in unstable coronary-artery disease: the FRISC-II invasive
randomised trial. FRISC-II Investigators. Fast Revascularisation dur-
ing Instability in Coronary artery disease. Lancet 2000;356:9–16.
5. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of
early invasive and conservative strategies in patients with unstable
coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor
tirofiban. N Engl J Med 2001;344:1879–87.
6. Fox KA, Poole-Wilson PA, Henderson RA, et al., on behalf of
Randomized Intervention Trial of unstable Angina Investigators.
Interventional versus conservative treatment for patients with unstable
angina or non–ST-elevation myocardial infarction: the British Heart
Foundation RITA 3 randomised trial. Randomized Intervention Trial
of unstable Angina. Lancet 2002;360:743–51.
7. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus
selectively invasive management for acute coronary syndromes. N Engl
J Med 2005;353:1095–104.
8. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an
interventional strategy in non–ST-elevation acute coronary syndrome:
Add to
score 
Age (years) <60 
0 
60-64 
+1 
65-69 
+2 
70-74 
+3 
≥75 
+5 
Diabetes No
0 
Yes 
+4 
Previous MI No 
0 
Yes 
+3 
ST-depression No
0 
Yes 
+2 
Hypertension No
0 
Yes 
+1 
BMI <25
+1 
25-<35 
0 
≥35 
+2 
Total Score 
Figure 6 Nomogram for Integer-Based Risk Score
for CV Death or MI at 5 Years
Integer risk score is the summation of integer values for each risk component.
Abbreviations as in Figure 2.the British Heart Foundation RITA 3 randomised trial. Lancet
2005;366:914–20.
K
i9. Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, Wallentin L.
5-year outcomes in the FRISC-II randomised trial of an invasive
versus a non-invasive strategy in non–ST-elevation acute coronary
syndrome: a follow-up study. Lancet 2006;368:998–1004.
0. Damman P, Hirsch A, Windhausen F, Tijssen JG, de Winter RJ,
ICTUS Investigators. 5-year clinical outcomes in the ICTUS (Invasive
versus Conservative Treatment in Unstable coronary Syndromes) trial:
a randomized comparison of an early invasive versus selective invasive
management in patients with non–ST-segment elevation acute coro-
nary syndrome. J Am Coll Cardiol 2010;55:865–6.
1. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the
diagnosis and treatment of non–ST-segment elevation acute coronary
syndromes. Eur Heart J 2007;28:1598–660.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007
guidelines for the management of patients with unstable angina/non–
ST-elevation myocardial infarction: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Revise the 2002 Guidelines for the
Management of Patients With Unstable Angina/Non–ST-Elevation
Myocardial Infarction). J Am Coll Cardiol 2007;50:157
3. National Institute for Clinical Excellence. NICE guideline: unstable
angina and NSTEMI: the early management of unstable angina and
non–ST-segment-elevation myocardial infarction. 2010. Available at:
http://guidance.nice.org.uk/CG/Wave14/24#keydocs. Accessed February
2, 2010.
4. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early
invasive therapy in acute coronary syndromes: a meta-analysis of contempo-
rary randomized clinical trials. J Am Coll Cardiol 2006;48:1319–25.
5. Qayyum R, Khalid MR, Adomaityte J, Papadakos SP, Messineo
FC. Systematic review: comparing routine and selective invasive
strategies for the acute coronary syndrome. Ann Intern Med
2008;148:186 –96.
6. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive
strategies in patients with acute coronary syndromes: a collaborative
meta-analysis of randomized trials. JAMA 2005;293:2908–17.
7. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed
invasive intervention in acute coronary syndromes. N Engl J Med
2009;360:2165–75.
8. Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of
periprocedural versus spontaneously occurring myocardial infarction after
percutaneous coronary intervention in patients with acute coronary syn-
dromes: an analysis from the ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;54:477–86.
9. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of
prolonged antithrombotic pretreatment (“cooling-off” strategy) before
intervention in patients with unstable coronary syndromes: a random-
ized controlled trial. JAMA 2003;290:1593–9.
0. Riezebos RK, Ronner E, Ter BE, et al. Immediate versus deferred
coronary angioplasty in non–ST-segment elevation acute coronary
syndromes. Heart 2009;95:807–12.
1. Lagerqvist B, Diderholm E, Lindahl B, et al. FRISC score for
selection of patients for an early invasive treatment strategy in unstable
coronary artery disease. Heart 2005;91:1047–52.
2. Wiviott SD, Braunwald E, McCabe CH, on behalf of the TRITON
Investigators. Prasugrel versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med 2007;357:2001–15.
3. Wallentin L, Becker RC, Budaj A, et al., on behalf of the PLATO
Investigators. Ticagrelor versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med 2009;361:1045–57.
4. Pocock SJ, Lubsen J. More on subgroup analyses in clinical trials. New
Engl J Med 2008;358:2076.
5. Bhatt DL, Roe MT, Peterson ED, et al., on behalf of the CRUSADE
Investigators. Utilization of early invasive management strategies for
high-risk patients with non–ST-segment elevation acute coronary
syndromes: results from the CRUSADE Quality Improvement Initia-
tive. JAMA 2004;292:2096–104.
6. Fox KAA, Anderson FA, Dabbous OH, et al., on behalf of the GRACE
Investigators. Intervention in acute coronary syndromes: do patients un-
dergo intervention on the basis of their risk characteristics? The Global
Registry of Acute Coronary Events (GRACE). Heart 2007;93:177–82.ey Words: acute coronary syndrome y percutaneous coronary
ntervention y interventional strategy.
